# Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

> **NCT04784000** · PHASE1 · COMPLETED · sponsor: **Atea Pharmaceuticals, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Healthy Volunteer Study

## Interventions

- **DRUG:** Period 1: AT-527 550 mg
- **DRUG:** Period 2: carbamazepine
- **DRUG:** Period 3: AT-527 550 mg + carbamazepine
- **DRUG:** Period 3: AT-527 1100 mg + carbamazepine

## Key facts

- **NCT ID:** NCT04784000
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2021-04-10
- **Final completion:** 2021-04-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04784000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04784000, "Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04784000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*